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Normalized ADCAim: To evaluate the potential value of the spleen and renal cortex as a reference organ to improve the
performance of DWI in the assessment of liver fibrosis.
Material and methods: 44 subjects were included: 30 patients with chronic viral hepatitis and 14 age
matched volunteers. They were subjected to diffusion weighted MRI (DWI). Liver ADC, normalized
ADC (ratio between ADC of liver to spleen (S-ADC) and renal cortex (R-ADC)) was calculated. Data was
analyzed and ROC was used to evaluate the performance of ADC, S-ADC and R-ADC.
Results: No significant difference between spleen ADC and renal ADC values between patient group and
control group or in-betweens different fibrosis stages. The mean liver ADC was significantly lower in cir-
rhotic patients than control group (1.59 ± 0.024 versus 1.55 ± 0.036  103 mm2/s, P = 0.009) with some
overlap in different fibrosis grades.
With exception to stage 1 fibrosis, the mean S-ADC value was significantly lower in patients with differ-
ent hepatic fibrosis stages in comparison to control group (P 0.02–<0.001). Significant negative correla-
tion was noted between S-ADC value and fibrosis stage (r = 0.75, p < 0.001). It had significant
difference between stage 0 compared to stage 2, 3, and 4 as well as between stage 4 in comparison to
stage 1, 2 and 3. S-ADC had a significant ability to differentiate between stages 0–1 Vs stage 2–4, stage
0–2 Vs stage 3–4 as well as stage 0–3 Vs stage 4.
Significant negative correlation was noted between R-ADC value and fibrosis stage (r = 0.68, p < 0.001).
The mean R-ADC value was lower in patients with liver fibrosis compared to volunteers with significant
difference between stage 0 and 3 and between stage 0 and 4 (P < 0.001). It had significant difference
between stage 0 compared to stage 3, and 4 as well as in stage 4 in comparison to stage 1 and 2.
R-ADC has a significant ability to differentiate between stages 0–1 Vs stage 2–4, stage 0–2 Vs stage
3–4 as well as stage 0–3 Vs stage 4.
ROC analysis showed higher performance using S-ADC in comparison to liver ADC and R-ADC while
R-ADC had higher performance in comparison to liver ADC. The AUC, sensitivity, specificity, PPV, NPV
and k-value for detection of fibrotic stages P2 (0.85, 95.8%, 60%, 74%, 92% and 0.85 for S-ADC Vs 0.68,
66.7%, 60%, 66%, 60% and 0.28 for ADC and 0.85, 95.8%, 50%, 69%, 91% and 0.47 for R-ADC). and in detec-
tion of fibrotic stagesP3 was (0.86, 100%, 52%, 61%, 100% and 0.48 for S-ADC Vs 0.63, 63%, 52%, 50%, 65%
and 0.14 for ADC and 0.88, 100%, 44%, 57%, 100% and 0.40 for R-ADC) while for fibrosis stage 4, the
corresponding values was (1, 100%, 100%, 100%, 100% and 1 for S-ADC Vs 0.7, 81%, 54%, 37%, 90% and
0.26 for ADC and 0.65, 100%, 65%, 45%, 100% and 0.43 for R-ADC) respectively.
Conclusion: Normalized liver ADC using the spleen and kidney increases the performance of ADC in the
evaluation of liver fibrosis which is highest in spleen normalized ADC.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
There are several causes that can lead to liver fibrosis as a long
run consequence of most important are viral, metabolic, autoim-
mune, cholestatic and alcohol or drug-induced diseases. Liver
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in liver cirrhosis, hepatic dysfunction and portal hypertension
[1–8].
Treatment of early fibrosis can be achieved by removing the
causing agent in consistent with the usage of specific antifibrotic
therapy hoping to reverse that early changes occurred. Hence it
is of great value to rule out the early liver fibrosis [1,2,6]. While
the liver biopsy and histological analysis is widely assigned as
the gold standard for assessment of hepatic fibrosis, it carries some
disadvantage. First it is relatively invasive with pain occurring in
about 40% while major complications can occur in 0.5% of suscep-
tible patients. Secondly, sample error liability and variation of
results in between different observers or even in same observer
with the difficulty of re-biopsy. Therefore, elaborating as reliable
and non-invasive diagnostic tools for hepatic fibrosis with quantifi-
cation capabilities is a real challenge [2,8,9–15].
Diffusion weighted MRI (DW-MRI) is a technique that mapping
and quantifies the water molecules motion in tissues and therefore
generates image contrast based on differences in its proton mobil-
ity in tissues. Quantification of water diffusion is done by the cal-
culation of the apparent diffusion coefficient (ADC) [14,16].
DW-MRI carries frequent advantages, for example it is rapid
(can be done in a breath-hold) and needs no contrast media. Recent
advancement in technology are supporting the progressive appli-
cation of DW-MRI in the abdomen including liver fibrosis with
improving and promising results [14,16–20].
Restriction of the apparentwater protondiffusionoccurs inhighly
cellular tissues andwith the higher density of cellmembranes.While
higher water molecules movement occurs in cystic or necrotic
tissues. Liver fibrosis results in the accumulation of collagen,
proteoglycan and glycosaminoglycans in the extracellular spaces so
subsequent water molecular restriction happens [2,14,16,21].
The application of normalization of ADC by using a reference
organ aims to reduce the ADC calculation variability. Spleen and
renal cortex can be tried to be the reference organs [20,22–25].
The aim of the current study was to evaluate the potential value
of using the spleen and renal cortex as a reference organ to normal-
ize liver ADC in order to improve the performance of DWI in the
assessment of liver fibrosis.Fig. 1. ADC map. ROI application for the liver (a), spleen (b) and (c).2. Material and methods
2.1. Subjects
The current study was approved by our institutional review
board. Written informed consent was obtained from all subjects.
This prospective study included a total of 35 consecutive
patients who was already diagnosed as chronic viral hepatitis on
basis of clinical findings and enhanced by laboratory investigations
and ongoing to percutaneous liver biopsy with normal renal
function tests. Of these 35 patients, 30 patients were included in
this study (patient group) with mean age 46.5 years (range
31–60 years), while 5 patients were excluded. Exclusion was due
to liver biopsy contraindication (n = 3), absolute contraindication
to MR study (n = 1) while last excluded patient was due to his refu-
sal to proceed to MR study.
Fourteen control matched age subjects were enrolled with
mean age 47 years (range 32–58 years), so total subjects in our
study was 44 (30 males, 14 females) with mean age 47 years
(range 31–60 years).
Patient group: Include thirty patients (21 males, 9 females) who
were previously diagnosed as chronic viral hepatitis.
Control group: Include fourteen matched age volunteers (9 men
and 5 women). Criteria of control group: have no absolutePlease cite this article in press as: Taha Ali TF, El Hariri MA. . Egypt J Radiol Ncontraindication to MRI imaging, no history of acute or chronic
hepatitis or diffuse hepatic disease and normal liver and renal
clinical, laboratory and imaging findings apart from small hep-
atic cyst or haemangioma.
2.2. MRI protocol
1.5 T MR scanner (Philips Medical Systems, Achieva) was used.
Phased array superficial body coil was applied. Single-shot echo-
planar imaging (EPI) sequence was used to obtain DWI in a single
end-expiratory breath-hold (free breathing and finger triggering
pulse).
MRI parameter: TR/TE: 1300–3500, 67–83 m/s, slice thickness:
7 mm, interslice gap: 1.5 mm, field of view: 320–420 mm. number
of signals averaged: 2. matrix: 192  256. Voxel size: 2.05 and 2.45
and tri-directional diffusion gradients (b = 500 s/mm2). Average
scan time: 6 min.
2.3. ADC mapping
A workstation with a standard software was used to obtain ADC
maps for b value = 500. The mean signal intensity (SI) wasucl Med (2016), http://dx.doi.org/10.1016/j.ejrnm.2016.11.004
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(ROIs; ranging from 10 to 20 mm2) in the liver, spleen and renal
cortex on ADC map with avoidance of vessels, artifacts and focal
lesions.
Hepatic ADC was calculated as the average of the four ROIs
applied to left lateral, left medial, right anterior and right posterior
liver segments on 3 contiguous slices.
For the spleen ADC: 2 ROIs were positioned 3 contiguous sec-
tions with a central slice through splenic hilum level, then average
was calculated.
For the renal ADC: 2 ROIs were placed at renal cortex of each
kidney on 3 contiguous sections with the central one through the
mid-pole level, the average was calculated.
Normalized hepatic ADC was calculated as the ratio between
the hepatic ADC to each of spleen ADC (S-ADC) and renal cortex
(R-ADC) (Fig. 1).
2.3.1. Histopathologic examination
All patients in the patient group (thirty) had percutaneous liver
biopsy that was done after the MRI examination (mean delay,
30 days; range, 10–52 days). Sonographic guidance was used to
do biopsy by an experienced hepatologist using a needle of 18–
20 gauges through trans- or sub costal approach. The right hepatic
lobe was sampled. The specimens length ofP1.5 cm were fixed in
formalin and stained with hematoxylin–eosin, stain for reticulin,Fig. 2. DWI at b = 0 (a), b = 500 (b), and ADC map (c) for a volunteer (stage 0
fibrosis): liver ADC = 1.61  103 mm2/s, S-ADC = 1.40 and R-ADC = 0.69.
Please cite this article in press as: Taha Ali TF, El Hariri MA. . Egypt J Radiol Nand Masson trichrome. The biopsy specimens should include
P10 portal tracts and regenerating nodules to be satisfactory.
Patients were classified according to the METAVIR scoring sys-
tem criteria which composed of F0: normal/no scarring, F1:mini-
mal scarring, F2: Scarring which extends outside the blood
vessels contained areas, F3: Bridging fibrosis, F4: cirrhosis [26].
2.3.2. Data analysis
A commercially available PC-based software package (SPSS) is
used for data analysis and to test significance of statistical differ-
ence. The specificity, sensitivity and accuracy of liver ADC as well
as S-ADC and R-ADC were calculated. Comparison between two
groups was done using Student’s t-test while one Way Anova test
was applied for comparison between more groups. Pearson’s corre-
lation between the liver ADC, S-ADC and R-ADC values and patho-
logical grade was done. Cohen’s kappa (j) is used to measures
inter-rater agreement.
MCnemar test was used to calculate concordance between the
ADC and normalized ADC values.
Analysis of receiver operating characteristic (ROC) curve and
the area under the ROC curve (AUC) was done. The threshold
ADC, S-ADC, R-ADC for the maximum sensitivity, specificity, posi-
tive predictive value (PPV), negative predictive value (NPV) and
overall accuracy in the differentiation between different stageFig. 3. DWI at b = 0 (a), b = 500 (b), and ADC map (c) for a patient with stage 1: liver
ADC = 1.57  103 mm2/s, S-ADC = 1.36 and R-ADC = 0.68.
ucl Med (2016), http://dx.doi.org/10.1016/j.ejrnm.2016.11.004




The prevalence of fibrosis stage (F) in the current study was:
stage 0 (control group; n = 14, Fig. 2), F1 (n = 6, Fig. 3), F2 (n = 5,
Fig. 4), F3 (n = 8, Fig. 5) and F4 (cirrhosis, n = 11, Fig. 6).
There was no significant difference between spleen ADC and
renal ADC values between patient group and control group
(1.03 ± 0.06 Vs 1.13 ± 0.09  103 mm2/s, p = 0.928 for spleen
ADC and 2.48 ± 0.09 Vs 2.49 ± 0.08  103 mm2/s, p = 0.937 for
renal ADC respectively), moreover no significant difference was
detected in neither of the spleen or renal ADC among patients with
different stages of fibrosis (p = 0.68–0.91) (see Fig. 7).
The mean liver ADC value in volunteers was
1.59 ± 0.024  103 mm2/s while in patient group was
1.56 ± 0.044  103 mm2/s. The mean liver ADC value was signifi-
cantly lower in cirrhotic patients (F4) in comparison to control
group (1.59 ± 0.024 versus 1.55 ± 0.036  103 mm2/s, P = 0.009).
On the other hand liver ADC had some overlap in different fibrosis
grades with insignificant difference between individual stage whileFig. 4. DWI at b = 0 (a), b = 500 (b), and ADC map (c) for a patient with stage 2. Liver
ADC = 1.56  103 mm2/s, S-ADC = 1.34 and R-ADC = 0.66.
Please cite this article in press as: Taha Ali TF, El Hariri MA. . Egypt J Radiol Nsignificance is noted in differentiation only between stage 0–1 Vs
stage 2–4 (p = 0.02) and between stage 0–3 Vs stage 4.
Significant negative correlation was noted between liver ADC
value and fibrosis stage (r = -0.35, p < 0.05) (Tables 1 and 2).
The mean S-ADC value in the control group was 1.39 ± 0.059
while in patient group it was 1.295 ± 0.053.
With exception to stage 1 fibrosis, the mean S-ADC value was
significantly lower in patients with different hepatic fibrosis stages
in comparison to control group (P 0.02–<0.001).
S-ADC value decreased with upgrading of fibrosis stage with
some overlapping in different fibrosis stages. It had significant dif-
ference between stage 0 compared to stage 2, 3, and 4 as well as
between stage 4 in comparison to stage 1, 2 and 3. On the other
hand there was no significant difference between the other stages.
S-ADC has a significant ability to differentiate between stages
0–1 Vs stage 2–4, stage 0–2 Vs stage 3–4 as well as stage 0–3 Vs
stage 4 (Tables 1 and 2).
Significant negative correlation was noted between S-ADC value
and fibrosis stage (r = 0.75, p < 0.001).
The mean R-ADC value in the control group was 0.69 ± 0.036
while in patient group it was 0.64 ± 0.114.
The mean R-ADC value was lower in patients with liver fibrosis
compared to volunteers with significant difference between stage
0 and 3 and between stage 0 and 4 (P < 0.001).Fig. 5. DWI at b = 0 (a), b = 500 (b) and ADC map(c) for a patient with stage 3. Liver
ADC = 1.57  103 mm2/s, S-ADC = 1.32 and R-ADC = 0.64.
ucl Med (2016), http://dx.doi.org/10.1016/j.ejrnm.2016.11.004
Fig. 6. DWI at b = 0 (a), b = 500 (b), and ADC map (c) for a patient with stage 4. Liver
ADC = 1.54  103 mm2/s, S-ADC = 1.20 and R-ADC = 0.60.
Fig. 7. ROC curves for liver ADC, S-ADC and R-ADC in differentiation of patients
stratified by fibrosis stage (distinguishing of stage P2 (a); distinguishing of
stageP 3 (b); and distinguishing of cirrhosis [stage 4] (c). Refer to Table 3 for AUC
values.
T.F. Taha Ali, M.AbdelGhaffar El Hariri / The Egyptian Journal of Radiology and Nuclear Medicine xxx (2016) xxx–xxx 5R-ADC value decreased with upgrading of fibrosis stage with
some overlapping in different fibrosis stages. It had significant dif-
ference between stage 0 compared to stage 3, and 4 as well as in
stage 4 in comparison to stage 1 and 2. On the other hand there
was no significant difference between other stages.
R-ADC has a significant ability to differentiate between stages
0–1 Vs stage 2–4, stage 0–2 Vs stage 3–4 as well as stage 0–3 Vs
stage 4 (Tables 1 and 2).
Significant negative correlation was noted between R-ADC
value and fibrosis stage (r = 0.68, p < 0.001).
ROC analysis (Fig. 6 and Table 3) showed higher performance
using S-ADC in comparison to liver ADC and R-ADC while R-ADC
had higher performance in comparison to liver ADC. The AUC, sen-
sitivity, specificity, PPV, NPV and k-value for detection of fibrotic
stages P2 (0.85, 95.8%, 60%, 74%, 92% and 0.85 for S-ADC Vs
0.68, 66.7%, 60%, 66%, 60% and 0.28 for ADC and 0.85, 95.8%, 50%,
69%, 91% and 0.47 for R-ADC).
In the detection of fibrotic stages P3, ROC analysis showed
higher performance using R-ADC in comparison to liver ADC while
S-ADC had a higher performance than both liver ADC and R-ADC.
The AUC, sensitivity, specificity, PPV, NPV and k-value (0.86,
100%, 52%, 61%, 100% and 0.48 for S-ADC Vs 0.63, 63%, 52%, 50%,
65% and 0.14 for ADC and 0.88, 100%, 44%, 57%, 100% and 0.40
for R-ADC).Please cite this article in press as: Taha Ali TF, El Hariri MA. . Egypt J Radiol NIn fibrosis stage 4, S-ADC had an overall higher performance
also in comparison to liver ADC and R-ADC while R-ADC had a
higher performance in comparison to liver ADC. The AUC, sensitiv-
ity, specificity, PPV, NPV and k-value (1, 100%, 100%, 100%, 100%
and 1 for S-ADC Vs 0.7, 81%, 54%, 37%, 90% and 0.26 for ADC and
0.65, 100%, 65%, 45%, 100% and 0.43 for R-ADC).ucl Med (2016), http://dx.doi.org/10.1016/j.ejrnm.2016.11.004
Table 1
The mean ADC (±SD) of: liver, S-ADC, R-ADC, in different grades of hepatic fibrosis
(according to METAVIR score).
Fibrosis stage No Liver ADC (103 mm2/s) S-ADC R-ADC
F0 14 1.59 ± 0.024 1.39 ± 0.059 0.69 ± 0.036
F1 6 1.57 ± 0.031 1.35 ± 0.06 0.67 ± 0.037
F2 5 1.56 ± 0.033 1.33 ± 0.051 0.67 ± 0.037
F3 8 1.57 ± 0.045 1.32 ± 0.021 0.63 ± 0.05
F4 11 1.55 ± 0.036 1.18 ± 0.023 0.62 ± 0.023
Table 2
ADC comparison among different fibrosis stages.
Liver ADC (P–value) S-ADC (P–value) R-ADC (P–value)
F0 Vs F1 0.43 0.11 0.19
F0 Vs F2 0.08 0.02 0.13
F0 Vs F3 0.40 0.005 <0.001
F0 Vs F4 0.009 <0.001 <0.001
F1 Vs F2 0.37 0.49 0.79
F1 Vs F3 0.98 0.32 0.06
F1 Vs F4 0.15 <0.001 0.01
F2 Vs F3 0.33 0.84 0.12
F2 Vs F4 0.73 <0.001 0.04
F3 Vs F4 0.11 <0.001 0.60
F0-1 Vs F2-4 0.02(S) <0.001 <0.001
F0-2 Vs F3-F4 0.10 <0.001 <0.001
F0-3 Vs F4 0.02(S) <0.001 0.002
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Applications of diffusion-weighted imaging (DWI) as a part of
abdominal MRI had become feasible with the advancement
of MRI techniques. Many authors have evaluated the application
of measuring the apparent diffusion coefficient (ADC) as a part of
evaluation of hepatic diseases [9,27–29]. Many literature had
demonstrated the significance of ADC reduction in cirrhotic livers
compared to the normal livers [8,10,14,16–20,30].
Girometti et al. [13] showed lower liver ADC in cirrhotic livers
compared to healthy controls, and reported an area under the
curve (AUC) of 0.93 for diagnosis of fibrosis, with sensitivity and
specificity of 89.7% and 100% respectively in differentiating for
diagnosing cirrhosis (using b-values of 0–150–250–400 s/mm2).
In another study [2] ADC was able to differentiate cirrhotic liver
from non-cirrhotic liver with lower ADC of the former, however in
that study ADC could not significantly differentiate between low
and high fibrosis grade. This is also confirmed by Razek et al. [8]
who also showed significant correlation between the mean ADC
value with METAVIR fibrosis score (r = 0.77, P = 0.01) and Taouli
et al. [14] who showed also lower liver ADCs in stage Pstage 2
compared to stage 61.
In this study, we have confirmed this opinion, as we found that
the mean liver ADC value in hepatic cirrhosis patients was signifi-Table 3
Analysis for performance of Liver ADC versus S-ADC and R-ADC:
Fibrosis stage ADC Cutoff (103 mm2/s) AUC Sensitivi
FP 2 ADC 1.58 0.68 66.7
S-ADC 1.36 0.85 95.8
R-ADC 0.70 0.85 95.8
FP 3 ADC 1.58 0.63 63
S-ADC 1.36 0.86 100
R-ADC 0.69 0.88 100
F = 4 ADC 1.58 0.7 81
S-ADC 1.25 1.0 100
R-ADC 0.65 0.65 100
Please cite this article in press as: Taha Ali TF, El Hariri MA. . Egypt J Radiol Ncantly lower than that of control normal group (1.55 ± 0.036 
103 mm2/s vs. 1.59 ± 0.024  103 mm2/s, p = 0.009). This can be
explained by the restricted diffusion in fibrotic changes due to
presence of collagen and thus reduction of liver ADC values [31].
We also noticed a significant negative correlation between liver
ADC value and stage of fibrosis (r = 0.35, p < 0.05). This is in
agreement with multiple previous studies [14–16,18,20,25,30] that
emphasized upon this negative correlation.
However this negative correlation was denied by Boulanger
et al. [17], who compared ADC values and fibrosis scores measured
using the Ishak scale with five different b values (50–50 s/mm2).
Limitations of the absolute ADC values are attributed to repro-
ducibility and noise effects as well as variability due to technical
factors as using different b values and acquisition methods as a
recognized problem [21,32–35].
The ideal b-value used in the assessment of hepatic fibrosis has
not yet been fully established and may depend on the individual
experiences [13,16,34–36]. ADC calculation using images obtained
with higher b values are more sensitive to diffusion than those
obtained using b values <500 s/mm2. On the other hand higher b
value of 800 s/mm2 are less sensitive to the effects of microvascu-
lar perfusion which is diminished in early fibrosis, till the present
time, the recommended b-value to obtain enough signals from
the liver is limited up to 500 mm2/s [8,14,16,19,31]. Chandarana
and Taouli [16] used b value of 0 and 400 while Do et al. [37] mea-
sured signal intensity on b0 and b 500. In current study we used b-
value of 0 and 500 s/mm2.
This was shown in a previous study [13] which reported cir-
rhotic liver ADCs of 1.14  103 mm2/s with b values of 0, 50,
250, and 400 s/mm2 and ADCs of 0.91  103 mm2/s with b values
of 600 and 800 s/mm2. Similar discrepancy was obtained in
another study [10] between the normal liver mean ADCs between
using b values of 0 and 500 s/mm2 (ADC was 1.79 ± 0.32 
103 mm2/s versus 1.55 ± 0.29  103 mm2/s).
So, application of a reference relatively constant organ for nor-
malization of ADC may help to diminish the variability in ADC cal-
culation. The spleen and renal cortex had been tried as a standard
Refs. [10,29,36–39].
In a previous study [20], the spleen ADCs showed insignificant
difference among healthy and chronic liver disease subjects. This
is consistent with the current study as we noticed insignificant dif-
ference of spleen ADC between patient and control group
(1.13 ± 0.09  103 mm2/s Vs 1.03 ± 0.06  103 mm2/s, p = 0.928),
or even among different stages of fibrosis (p = 0.54–0.91).
In addition, Insignificant difference of renal cortex ADC is noted
also in current study between patient and volunteer group
(2.48 ± 0.09  103 mm2/s Vs 2.49 ± 0.08  103 mm2/s, p = 0.937),
as well as among different stages of fibrosis (p = 0.61–0.87).
In our current study, the mean R-ADC value was lower in
patients with liver fibrosis compared to volunteers with significant
difference between stage 0 and 3 and between stage 0 and 4
(P < 0.001). R-ADC value decreased with upgrading of fibrosis stagety (%) Specificity (%) PPV NPV KAPPA P-value
60.0 66 60 0.28 0.07
60 74 92 0.58 <0.001
50 69 91 0.47 <0.001
52 50 65 0.14 0.31
52 61 100 0.48 <0.001
44 57 100 0.40 <0.001
54 37 90 0.26 0.03
100 100 100 1.0 <0.001
65 45 100 0.43 <0.001
ucl Med (2016), http://dx.doi.org/10.1016/j.ejrnm.2016.11.004
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difference between stage 0 compared to stage 3, and 4 as well as in
stage 4 in comparison to stage 1 and 2. On the other hand there
was no significant difference between the other stages. R-ADC
has a significant ability to differentiate between stages 0–1 Vs
stage 2–4, stage 0–2 Vs stage 3–4 as well as stage 0–3 Vs stage 4.
In the study carried out by Hong et al. [36], to compare the
accuracy of normalized spleen and renal ADC, they reported signif-
icant reduction of normalized renal ADC (R-ADC) with higher fibro-
sis stages at variable b value with higher accuracy at b = 600 s/mm2
(r = 0.697; p < 0.001), they showed that R-ADC at 3 T with b-value
of 600 s/mm2 might be more accurate than normalized spleen
R-ADC in prediction of hepatic fibrosis.
On the other hand another study [38] compared the diagnostic
accuracy of using the spleen and renal cortex as reference organ for
normalized liver ADC. They showed that the S-ADC has a higher
accuracy in the diagnosis of liver fibrosis in comparison to liver
ADC and R-ADC. S-ADC had higher accuracy also in detection of
fibrosis stage 2, 3 and 4. They also showed stronger correlation
between fibrosis stage and S-ADC compared to liver ADC and
R-ADC (r = 0.71, 0.51, 0.41 respectively; P < 0.01).
In this study, we found a significant negative correlation
between each of ADC, S-ADC and R-ADC with the fibrosis grade.
This correlation was higher in S-ADC (r = 0.75, p < 0.001) than
R-ADC (r = 0.68, p < 0.001), and more powerful for R-ADC com-
pared to liver ADC.
In current study, the mean S-ADC value was significantly lower
in patients with different hepatic fibrosis stages in comparison to
control group except for stage 1 (P 0.02–<0.001). It could signifi-
cantly differentiate stage 0 from stage 2, 3, and 4 as well as stage
4 from all other stages, while no significance was noted between
the other stages. S-ADC has a significant ability to differentiate
between stages 0–1 Vs stage 2–4, stage 0–2 Vs stage 3–4 as well
as stage 0–3 Vs stage 4.
This enhanced the opinion of the previous report [37] for
encouraging the usage of the spleen as a reference organ in order
to increase the capability of ADC in the detection of cirrhosis. In
that study Absolute hepatic ADCs in cirrhosis were lower than nor-
mal livers but not reaching significant levels (1.67 ± 0.26  103
versus 1.81 ± 0.36  103 mm2/sec, p = 0.33) while they reported
significant R-ADC differences between cirrhotic and non-cirrhotic
cases (1.25 ± 0.22 vs. 1.55 ± 0.22, p = 0.02). The authors proposed
a cutoff <1.4 to have a specificity and sensitivity of 80% and 78%
respectively in the diagnosis of cirrhosis. They concluded that nor-
malized liver ADC may be of value in the detection of early cir-
rhotic changes in normal appearing liver on conventional MR
images.
This is also in consistent with an earlier report [10] which
showed the inability of the liver ADC discriminate between differ-
ent fibrosis stages except between 0 and 4.
On the other hand S-ADC had a significant difference between
normal livers and stage 2–3 (intermediate fibrosis) and stage 4
(cirrhosis). Also significant difference was detected between stage
1 and 4. A trend toward significance was noted between stages 0
and 1 (p = 0.051) and stages 1 and 3 (p = 0.06). Some previous stud-
ies using liver ADC had estimated AUC values of 0.655–0.790,
0.689–0.92 and 0.720–0.93 for the detection of liver fibrosis stage
P2, stage P3 and cirrhosis respectively [10,11,13,14].
In an earlier report [10] ROC analysis showed the superiority of
S-ADC in comparison to liver ADC in the detection of stage P2
(AUC: 0.864 Vs 0.655; p = 0.013) and stage P3 (0.805 Vs 0.689;
p = 0.015), while no significant difference was found in patients
of cirrhosis (0.935 vs. 0.720; p = 0.185).
In the current study, ROC analysis showed higher performance
using S-ADC in comparison to liver ADC and R-ADC while R-ADC
had higher performance in comparison to liver ADC. The AUC, sen-Please cite this article in press as: Taha Ali TF, El Hariri MA. . Egypt J Radiol Nsitivity, specificity, PPV, NPV and k-value for detection of fibrotic
stages P2 (0.85, 95.8%, 60%, 74%, 92% and 0.85 for S-ADC Vs
0.68, 66.7%, 60%, 66%, 60% and 0.28 for ADC and 0.85, 95.8%, 50%,
69%, 91% and 0.47 for R-ADC).
In the detection of fibrotic stages P3, ROC analysis showed
higher performance using R-ADC in comparison to liver ADC while
S-ADC had a higher performance than both liver ADC and R-ADC.
The AUC, sensitivity, specificity, PPV, NPV and k-value (0.86,
100%, 52%, 61%, 100% and 0.48 for S-ADC Vs 0.63, 63%, 52%, 50%,
65% and 0.14 for ADC and 0.88, 100%, 44%, 57%, 100% and 0.40
for R-ADC).
In fibrosis stage 4, S-ADC had an overall higher performance
also in comparison to liver ADC and R-ADC while R-ADC had a
higher performance in comparison to liver ADC. The AUC, sensitiv-
ity, specificity, PPV, NPV and k-value (1, 100%, 100%, 100%, 100%
and 1 for S-ADC Vs 0.7, 81%, 54%, 37%, 90% and 0.26 for ADC and
0.65, 100%, 65%, 45%, 100% and 0.43 for R-ADC).
The current results are also in consistent with the previous
report [38] which concluded that the usage of spleen for normal-
ization of liver ADC can improve the potential accuracy in the
detection of liver fibrosis in comparison to liver ADC and renal nor-
malized liver ADC.
We had some limitations in current study. Variability of interval
time between MRI performance and biopsy taking (mean delay,
30 days; range, 10–52 days) during which the fibrosis may under-
goes progression or alteration of its degree due to ongoing medical
treatment. Small number of subjects enrolled in this study was
another obstacle.
In conclusion, the current results highlighted the value of appli-
cation of normalized liver ADC using the spleen and kidney as ref-
erence organs to increase the performance of ADC measurement in
the evaluation of liver fibrosis. Spleen normalized ADC had the
highest performance power over ADC and renal normalized ADC.
The usage of this tool has a promising result in the assessment of
liver fibrosis that may assist to avoid or at least reduce the liver
biopsies in some patients.References
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